Search
for
Sort by
Research 30 of 346
- Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF V 600R mutation
- 42761 The elusive BAP1 mutation in pediatric melanocytic tumors
- Hair(y) Matters in Melanoma Biology
- At the Root: Cutaneous Langerhans Cell Histiocytosis
- Dyad of infantile cutaneous and thymic Langerhans cell histiocytosis: Is it rare?
- Decision letter: Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
- Author response: Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Author response: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy?
- Decision letter: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Diagnosis and Management of Melanoma of the Scalp: A Review of the Literature
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- Biological therapy in the treatment of melanoma
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- B‐ RAF , naevi and melanoma: a complex relationship
- Somatic mutations distinguish melanocyte subpopulations in human skin
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- 414 A new form of ectodermal dysplasia caused by mutations in TSPEAR